Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic H...
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer
About this item
Full title
Author / Creator
Mondaca, Sebastian , Margolis, Matthew , Sanchez-Vega, Francisco , Jonsson, Philip , Riches, Jamie C. , Ku, Geoffrey Y. , Hechtman, Jaclyn F. , Tuvy, Yaelle , Berger, Michael F. , Shah, Manish A. , Kelsen, David P. , Ilson, David H. , Yu, Kenneth , Goldberg, Zoe , Epstein, Andrew S. , Desai, Avni , Chung, Vincent , Chou, Joanne F. , Capanu, Marinela , Solit, David B. , Schultz, Nikolaus and Janjigian, Yelena Y.
Publisher
Singapore: Springer Singapore
Journal title
Language
English
Formats
Publication information
Publisher
Singapore: Springer Singapore
Subjects
More information
Scope and Contents
Contents
Background
Trastuzumab with cisplatin and fluoropyrimidine is the standard treatment in metastatic HER2-positive gastric or gastroesophageal (GE) junction adenocarcinoma; however, there is limited data on the efficacy of trastuzumab in combination with a three-drug regimen in this setting. We examined the efficacy and safety of modified docetaxe...
Alternative Titles
Full title
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer
Authors, Artists and Contributors
Author / Creator
Margolis, Matthew
Sanchez-Vega, Francisco
Jonsson, Philip
Riches, Jamie C.
Ku, Geoffrey Y.
Hechtman, Jaclyn F.
Tuvy, Yaelle
Berger, Michael F.
Shah, Manish A.
Kelsen, David P.
Ilson, David H.
Yu, Kenneth
Goldberg, Zoe
Epstein, Andrew S.
Desai, Avni
Chung, Vincent
Chou, Joanne F.
Capanu, Marinela
Solit, David B.
Schultz, Nikolaus
Janjigian, Yelena Y.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2084663941
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2084663941
Other Identifiers
ISSN
1436-3291
E-ISSN
1436-3305
DOI
10.1007/s10120-018-0861-7
